yok
-
Sayın editörlermize saygılarımla
Aims: This study aims to determine the prognostic significance of the pretreatment albumin/alkaline phosphatase ratio (AAPR) for overall survival in patients diagnosed with metastatic lung adenocarcinoma (MLA).
Methods: The medical records of 459 patients diagnosed with MLA between 2010 and 2021 were retrospectively reviewed. The AAPR was calculated using blood test results obtained at the time of diagnosis.
Results: The study identified the optimal threshold value for AAPR as 0.314. Patients with a high AAPR (AAPR>0.314) demonstrated significantly longer median survival and overall survival time compared to those with a low AAPR (AAPR ≤ 0.314) (p<0.001). Specifically, the median survival time for the low AAPR group was 2.13±0.29 (95% CI: 1.56-2.70) months, while the high AAPR group had a median survival time of 4.1±0.59 (95% CI: 2.90-5.23) months (p<0.001). The 1-year survival rates were 27.3% and 5.3% for the high and low AAPR groups, respectively (p<0.001). Additionally, an AAPR ≤ 0.314 increased the risk of death by 1.96 times at 1 year.
Conclusion: The AAPR was significantly reduced in MLA patients, making it a significant biomarker for forecasting prognosis and directing treatment options for these patients.
Metastatic Lung Adenocarcinoma Albumin-to-Alkaline Phosphatase Ratio prognostic factor survival
-
Primary Language | English |
---|---|
Subjects | Chest Diseases |
Journal Section | Original Article |
Authors | |
Project Number | - |
Early Pub Date | October 28, 2023 |
Publication Date | October 29, 2023 |
Published in Issue | Year 2023 Volume: 6 Issue: 6 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.